FindTrial
Sign In

A prospective observational study evaluating intestinal microbiome as a biomarker to predict the efficacy and toxicity of prostate cancer patients receiveing PARP inhibitors alone or combined with novel ADT agents

A prospective observational study evaluating intestinal microbiome as a biomarker to predict the efficacy and toxicity of prostate cancer patients receiveing PARP inhibitors alone or combined with novel ADT agents

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100047230
Enrollment
Unknown
Registered
2021-06-11
Start date
2021-07-01
Completion date
Unknown
Last updated
2022-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Interventions

case series:None

Sponsors

Fudan University Shanghai Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Pathologically confirmed prostate cancer; 2. Estimated survival time >= 3 months.

Exclusion criteria

Exclusion criteria: 1. Those who have used other PARP inhibitors in the past; 2. Patients who are clinically judged unsuitable for treatment with PARP inhibitors.

Design outcomes

Primary

MeasureTime frame
side effects;—

Countries

China

Contacts

Public ContactYe Dingwei

Fudan University Shanghai Cancer Center

dingwei_ye1963@163.com+86 13701663571

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026